Triumeq
Active Ingredient(s): Abacavir Sulfate + Dolutegravir + LamivudineFDA Approved: * August 22, 2014
Pharm Company: * VIIV HLTHCARE
Category: HIV / AIDS
Abacavir/dolutegravir/lamivudine (brand name Triumeq) is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It is a combination of three medications with different and complementary mechanisms of action: 600mg abacavir (reverse transcriptase inhibitor), 50mg dolutegravir (integrase inhibitor) and 300mg lamivudine (nucleoside analog reverse transcriptase inhibitor). The medication was developed by ViiV Healthcare and was approved for use in the United States and... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.